CYCC insider filings

Cyclacel Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-09-10. Screen CYCC transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CYCC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Cyclacel Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2025-09-104Kua Khai Loon — 10% ownerSale (S): 19,054 @ $7.01EDGAR
2025-09-044Kua Khai Loon — 10% ownerOther (J): 186,465 · Other (J): 186,465 (derivative) @ $0EDGAR
2025-09-044Yap Kim Choy — 10% ownerOther (J): 186,465 · Other (J): 186,465 (derivative) @ $0EDGAR
2025-09-044Ong Yee Lung — 10% ownerOther (J): 186,465 · Other (J): 186,465 (derivative) @ $0EDGAR
2025-08-044Lazar David E. — 10% ownerSale (S): 6,750 @ $12.36EDGAR
2025-02-284NATAN DAVID — DirectorGrant/award (A): 700,000 (derivative) @ $0EDGAR
2025-02-284Lazar David E. — Interim CEO, 10% ownerOption exercise (M): 2,650,000 · Option exercise (M): 191,978,820 · Sale (S): 194,628,820 @ $0.03 · Option exercise (M): 1,000,000 (derivative) · Option exercise (M): 1,745,262 (derivative)EDGAR
2025-02-284Ben-Tzvi Avraham — DirectorGrant/award (A): 700,000 (derivative) @ $0EDGAR
2025-02-104Lazar David E. — Interim CEO, 10% ownerGrant/award (A): 2,100,000 (derivative)EDGAR
2025-01-074NATAN DAVID — DirectorGrant/award (A): 100,000EDGAR
2024-01-314SCHWARTZ BRIAN — Interim Chief Medical Officer, DirectorGrant/award (A): 12,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0EDGAR
2023-12-264McBarron Paul — See Remarks, DirectorPurchase (P): 1,886 @ $3.31 · Purchase (P): 1,886 (derivative) @ $0EDGAR
2023-12-264Rombotis Spiro George — President and CEO, DirectorPurchase (P): 6,070 @ $3.31 · Purchase (P): 6,070 (derivative) @ $0EDGAR
2023-07-034Rombotis Spiro George — President and CEO, DirectorGrant/award (A): 110,000 (derivative) @ $0EDGAR
2023-07-034BARKER SAM L — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-07-034Spiegel Robert J. — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-07-034McBarron Paul — See Remarks, DirectorGrant/award (A): 70,200 (derivative) @ $0EDGAR
2023-07-034Kirschbaum Mark — Chief Medical OfficerGrant/award (A): 70,200 (derivative) @ $0EDGAR
2023-07-034Walker Karin L — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-07-034Ferguson Kenneth M. — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-07-034HENNEY CHRISTOPHER S — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-07-034SCHWARTZ BRIAN — DirectorGrant/award (A): 21,219 @ $0 · Grant/award (A): 42,438 (derivative) @ $0EDGAR
2023-02-024McBarron Paul — See Remarks, DirectorGrant/award (A): 31,200 @ $0EDGAR
2023-02-024Rombotis Spiro George — President and CEO, DirectorGrant/award (A): 57,600 @ $0EDGAR
2023-02-024Kirschbaum Mark — Chief Medical OfficerGrant/award (A): 31,200 @ $0EDGAR
2022-06-174/AFerguson Kenneth M. — DirectorGrant/award (A): 23,733 @ $0 · Grant/award (A): 47,467 (derivative) @ $0EDGAR
2022-06-164Ferguson Kenneth M. — DirectorGrant/award (A): 27,733 @ $0 · Grant/award (A): 47,467 (derivative) @ $0EDGAR
2022-06-164Walker Karin L — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2022-06-164Spiegel Robert J. — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2022-06-164Sems Lloyd — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2022-06-164SCHWARTZ BRIAN — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2022-06-164HENNEY CHRISTOPHER S — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2022-06-164BARKER SAM L — DirectorGrant/award (A): 15,822 @ $0 · Grant/award (A): 31,645 (derivative) @ $0EDGAR
2021-12-164/ARombotis Spiro George — President and CEO, DirectorGrant/award (A): 190,000 (derivative) @ $0EDGAR
2021-12-154Rombotis Spiro George — President and CEO, DirectorGrant/award (A): 190,000 (derivative) @ $0EDGAR
2021-12-154McBarron Paul — See Remarks, DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2021-12-154Kirschbaum Mark — Chief Medical OfficerGrant/award (A): 100,000 (derivative) @ $0EDGAR
2021-12-024BARKER SAM L — DirectorSale (S): 12 @ $3.57EDGAR
2021-11-224Rombotis Spiro George — President and CEO, DirectorPurchase (P): 4,000 @ $4.50EDGAR
2021-08-254BARKER SAM L — DirectorPurchase (P): 1,000 @ $5EDGAR
2021-06-174Hradsky Gregory T. — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0EDGAR
2021-06-174BARKER SAM L — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0EDGAR
2021-06-174Spiegel Robert J. — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0EDGAR
2021-06-174Sems Lloyd — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0EDGAR
2021-06-174HENNEY CHRISTOPHER S — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 4,748 (derivative) @ $0EDGAR
2021-06-174Walker Karin L — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 1,187 @ $0 · Grant/award (A): 4,748 (derivative) @ $0 · Grant/award (A): 2,374 (derivative) @ $0EDGAR
2021-06-174SCHWARTZ BRIAN — DirectorGrant/award (A): 2,374 @ $0 · Grant/award (A): 1,187 @ $0 · Grant/award (A): 4,748 (derivative) @ $0 · Grant/award (A): 2,374 (derivative) @ $0EDGAR
2020-12-214SCHWARTZ BRIAN — DirectorGrant/award (A): 5,200 (derivative) @ $0EDGAR
2020-12-154McBarron Paul — See Remarks, DirectorGrant/award (A): 120,000 (derivative) @ $0EDGAR
2020-12-154Rombotis Spiro George — President and CEO, DirectorGrant/award (A): 175,000 (derivative) @ $0EDGAR

Recent 8-K events — Cyclacel Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-208-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-048-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-168-K8.01 — Other EventsEDGAR
2026-08-148-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-018-K8.01 — Other EventsEDGAR
2026-06-228-K5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-108-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-048-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-148-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CYCC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs